Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial
Clicks: 1
ID: 314303
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #85 of 127 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 127 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Many factors contribute to muscle impairment during chronic kidney disease, within which vitamin D deficiency has been involved. The aim of this study was to analyze if cholecalciferol supplementation in hemodialysis patients with low 25-OH vitamin D (25OHD) concentrations could improve handgrip strength. Methods VITADIAL is a prospective open-labeled French multicenter study in which chronic hemodialysis patients with a 25OHD ≤ 50nmol/L were randomized to receive monthly oral 100.000 IU cholecalciferol or no vitamin D treatment during 6 months to assess if cholecalciferol supplementation in vitamin D deficient hemodialysis patients improves muscle strength as measured with handgrip strength (HGS). The main objective of the study was to analyze if a 6-month period of oral cholecalciferol improved the muscle strength of hemodialysis patients with low 25OHD levels. Results Within the 270 hemodialysis patients from 10 hemodialysis centers included in the study 143 patients with 25OHD ≤ 50nmol/L were randomized: 70 were allocated to the cholecalciferol group and 73 to the control group. The two groups were comparable at inclusion. The cholecalciferol supplemented group’s 25OHD raised to 89.78±33.43 nmol/L at 6 months and remained ≤50 nmol/L for most patients of the control group, but HGS did not change significantly between randomization and end of the study in both groups (0.07±3.40kg and -0.19±3.35kg respectively, p-value 0.682). No difference was found neither in terms of autonomy and frailty. Conclusions This highly powered study did not find any effect of cholecalciferol supplementation in muscle strength of hemodialysis patients with low 25OHD.
| Reference Key |
openalex_W7161969498
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Stanislas Bataille, Guillaume Séret, Frédéric Lavainne, Philippe Giaime, Marianne Serveaux, Thomas Robert, Mickael Bobot, Laurence Vrigneaud, Guillaume Jean, Louis de Laforcade, Mathilde Prezelin-Reydit, Philippe Chauveau, M. Isnard, Laurent Samson, Angélique Colin, Frederique Boury, A Viton, Magali Claeys-Bruno, Nathalie Pedinielli |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag166
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.